SHPH Stock Overview A clinical stage pharmaceutical company, develops novel therapies to cure cancers. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Shuttle Pharmaceuticals Holdings, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Shuttle Pharmaceuticals Holdings Historical stock prices Current Share Price US$0.88 52 Week High US$4.71 52 Week Low US$0.58 Beta 0.26 1 Month Change 37.48% 3 Month Change -33.33% 1 Year Change -73.62% 3 Year Change n/a 5 Year Change n/a Change since IPO -99.71%
Recent News & Updates
New major risk - Shareholder dilution Nov 29
Shuttle Pharmaceuticals Holdings, Inc. Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient Nov 26
New major risk - Negative shareholders equity Nov 15 Shuttle Pharmaceuticals Holdings, Inc. Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma Shuttle Pharmaceuticals Holdings, Inc. announced that it expects to receive $1.3 million in funding Oct 18
Shuttle Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering. Sep 20
See more updates
New major risk - Shareholder dilution Nov 29
Shuttle Pharmaceuticals Holdings, Inc. Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient Nov 26
New major risk - Negative shareholders equity Nov 15 Shuttle Pharmaceuticals Holdings, Inc. Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma Shuttle Pharmaceuticals Holdings, Inc. announced that it expects to receive $1.3 million in funding Oct 18
Shuttle Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering. Sep 20
Shuttle Pharmaceuticals Holdings, Inc. Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma Sep 16
Shuttle Pharmaceuticals Holdings Receives Non-Compliance Letter from Nasdaq Regarding Minimum Stockholders' Equity Requirement Sep 14
Shuttle Pharmaceuticals Provides Regains Compliance with Nasdaq Listing Rule 5250(c) Sep 05
Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement Aug 29
Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1) Aug 28
Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma Aug 15
Shuttle Pharmaceuticals Holdings, Inc. announced delayed 10-Q filing Aug 14
Shuttle Pharmaceuticals Holdings, Inc. Announces Publication of A Manuscript Reporting on the Ability of One of the Company’s HDAC Inhibitor Pre-Clinical Assets, SP-1-303 Jul 20 Shuttle Pharmaceuticals Holdings, Inc. Announces Chief Financial Officer Changes Jun 18
Shuttle Pharmaceuticals Holdings, Inc., Annual General Meeting, Jul 31, 2024 Jun 13
New major risk - Financial position May 15
New major risk - Financial position Mar 24
New minor risk - Share price stability Jan 22
Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma Jan 08
Shuttle Pharmaceuticals Holdings, Inc. Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma Dec 11
New minor risk - Share price stability Oct 25
Shuttle Pharmaceuticals Holdings, Inc., Annual General Meeting, Dec 18, 2023 Oct 22
Shuttle Pharmaceuticals Holdings, Inc., Annual General Meeting, Dec 18, 2023 Oct 21
Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma Sep 26
Shuttle Pharmaceuticals Holdings, Inc. Expands Patent Coverage on HDAC Inhibitor Platform Sep 12
Shuttle Pharmaceuticals Holdings Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Sep 08
New major risk - Financial position Aug 16
Shuttle Pharmaceuticals Holdings Files Form 10-Q with the Securities and Exchange Commission and Regains Compliance with the Nasdaq Listing Rules May 29
Shuttle Pharmaceuticals Holdings, Inc. announced delayed 10-Q filing May 16 Shuttle Pharmaceuticals Holdings, Inc. announced that it has received $4 million in funding from Ayrton Capital LLC Jan 13
Shuttle Pharmaceuticals Holdings, Inc. Announces the Publication of Manuscript Discussing Immune Responses Taking Place in Patients After Radiation Therapy for Cancer Jan 12
Insufficient new directors Nov 16
Shuttle Pharmaceuticals Holdings, Inc. Appoints Bette Jacobs to Its Board of Directors Nov 02
Shuttle Pharmaceuticals Holdings, Inc. Receives New HDAC Inhibitor Patents for Cancer Treatment Sep 16
Shuttle Pharma awarded new patents for its radiation sensitizing technology platform Sep 15
Shuttle Pharmaceuticals Holdings, Inc. has completed an IPO in the amount of $9.96034 million. Sep 01 Shareholder Returns SHPH US Biotechs US Market 7D 3.5% 3.6% 3.8% 1Y -73.6% -6.1% 24.4%
See full shareholder returns
Return vs Industry: SHPH underperformed the US Biotechs industry which returned -7.2% over the past year.
Return vs Market: SHPH underperformed the US Market which returned 23.7% over the past year.
Price Volatility Is SHPH's price volatile compared to industry and market? SHPH volatility SHPH Average Weekly Movement 16.2% Biotechs Industry Average Movement 11.3% Market Average Movement 6.5% 10% most volatile stocks in US Market 18.9% 10% least volatile stocks in US Market 3.2%
Stable Share Price: SHPH's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SHPH's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.
Show more Shuttle Pharmaceuticals Holdings, Inc. Fundamentals Summary How do Shuttle Pharmaceuticals Holdings's earnings and revenue compare to its market cap? SHPH fundamental statistics Market cap US$3.08m Earnings (TTM ) -US$9.19m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) SHPH income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$9.19m Earnings -US$9.19m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -2.51 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio -19.0%
How did SHPH perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/21 04:55 End of Day Share Price 2025/01/21 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Shuttle Pharmaceuticals Holdings, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
